{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:52:06Z","timestamp":1773953526594,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T00:00:00Z","timestamp":1622332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The pandemic of the coronavirus disease 2019 (COVID-19) represents an unprecedented challenge to identify effective drugs for prevention and treatment. While the world\u2019s attention is focused on news of COVID-19 vaccine updates, clinical management still requires improvement. Due to the similarity of cancer-induced inflammation, immune dysfunction, and coagulopathy to COVID-19, anticancer drugs, such as Interferon, Pembrolizumab or Bicalutamide, are already being tested in clinical trials for repurposing, alone or in combination. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected, clinicians need effective medical treatments for this infection.<\/jats:p>","DOI":"10.3390\/pharmaceutics13060815","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T01:51:37Z","timestamp":1622425897000},"page":"815","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-5874","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Costa","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/ijbs.45053","article-title":"SARS-CoV-2: An Emerging Coronavirus that Causes a Global Threat","volume":"16","author":"Zheng","year":"2020","journal-title":"Int J Biol Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00002512-200320030-00001","article-title":"Influenza vaccination and antiviral therapy: Is there a role for concurrent administration in the institutionalised elderly?","volume":"20","author":"Drinka","year":"2003","journal-title":"Drugs Aging"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Deb, P., Molla, M.A., and Saif-Ur-Rahman, K. (2021). An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf. Health.","DOI":"10.1016\/j.bsheal.2021.02.001"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3389\/fphar.2020.588654","article-title":"Challenges for drug repurposing in the COVID-19 pandemic era","volume":"11","author":"Sultana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118275","DOI":"10.1016\/j.lfs.2020.118275","article-title":"Utilizing drug repurposing against COVID-19\u2014Efficacy, limitations, and challenges","volume":"259","author":"Parvathaneni","year":"2020","journal-title":"Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41416-020-0948-x","article-title":"Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy","volume":"123","author":"Saini","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_9","unstructured":"(2021, February 06). National Center for Advancing Translational Sciences|OpenData Portal, Available online: https:\/\/opendata.ncats.nih.gov\/covid19\/databrowser."},{"key":"ref_10","unstructured":"(2021, February 06). ClinicalTrials.gov, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/home."},{"key":"ref_11","unstructured":"(2021, February 06). European Pharmaceutical Review|News. Available online: https:\/\/www.europeanpharmaceuticalreview.com\/."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Richman, D.D., and Nathanson, N. (2016). Antiviral Therapy. Viral Pathog., 271\u2013287.","DOI":"10.1016\/B978-0-12-800964-2.00020-3"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Romano, M., Ruggiero, A., Squeglia, F., Maga, G., and Berisio, R.A. (2020). Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells, 9.","DOI":"10.20944\/preprints202004.0510.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108630","DOI":"10.1016\/j.clim.2020.108630","article-title":"Major reduction of NKT cells in patients with severe COVID-19 pneumonia","volume":"222","author":"Zingaropoli","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_17","first-page":"1","article-title":"Endothelial activation and dysfunction in COVID-19: From basic mechanisms to potential therapeutic approaches","volume":"5","author":"Jin","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Boechat, J.L., Chora, I., Morais, A., and Delgado, L. (2021). The immune response to SARS-CoV-2 and COVID-19 immunopathology\u2013current perspectives. Pulmonology.","DOI":"10.1016\/j.pulmoe.2021.03.008"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.it.2015.09.007","article-title":"Interferons and the immunogenic effects of cancer therapy","volume":"36","author":"Minn","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: Success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107171","DOI":"10.1016\/j.intimp.2020.107171","article-title":"Potential role of interferons in treating COVID-19 patients","volume":"90","author":"Abdolvahab","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: The role of cytokines in COVID-19 disease","volume":"54","author":"Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","article-title":"Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex","volume":"290","author":"Lacroix","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Khan, F.A., Stewart, I., Fabbri, L., Moss, S., Robinson, K., Smyth, A.R., and Jenkins, G. (2021). Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax.","DOI":"10.1101\/2020.04.23.20076612"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sullivan, R.J., Johnson, D.B., Rini, B., Neilan, T.G., Lovly, C.M., Moslehi, J.J., and Reynolds, K.L. (2020). COVID-19 and immune checkpoint inhibitors: Initial considerations. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-000933"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","article-title":"T cell responses in patients with COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Saito, N., Yoshida, K., Okamoto, M., Sasaki, J., Kuroda, C., Ishida, H., Ueda, K., Ideta, H., Kamanaka, T., and Sobajima, A. (2019). Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer, 20.","DOI":"10.21203\/rs.2.12812\/v1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2217\/fon-2020-0571","article-title":"The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer","volume":"16","author":"Mollica","year":"2020","journal-title":"Future Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-1088-9","article-title":"Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer","volume":"3","author":"Chakravarty","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1021\/acs.jproteome.0c00397","article-title":"Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2","volume":"19","author":"Martin","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cheng, F., Rao, S., and Mehra, R. (2020). COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach. Cleve Clin. J. Med.","DOI":"10.3949\/ccjm.87a.ccc037"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"White, K.M., Rosales, R., Yildiz, S., Kehrer, T., Miorin, L., Moreno, E., Jangra, S., Uccellini, M.B., Rathnasinghe, R., and Coughlan, L. (2021). Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science, 926\u2013931.","DOI":"10.1126\/science.abf4058"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"112653","DOI":"10.1016\/j.ejmech.2020.112653","article-title":"Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses","volume":"203","author":"Nebigil","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12039","article-title":"Targeting phosphoinositide 3-kinase \u03b4 for the treatment of respiratory diseases","volume":"1280","author":"Sriskantharajah","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-020-00139-0","article-title":"Vitamin D and Covid-19: An update on evidence and potential therapeutic implications","volume":"18","author":"Murdaca","year":"2020","journal-title":"Clin. Mol. Allergy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"ref_38","unstructured":"(2020, January 03). Repurposed Drugs with Broad-Spectrum Antiviral Activity, by BioRender.com. Available online: https:\/\/app.biorender.com\/biorender-templates."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/6\/815\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:08:59Z","timestamp":1760162939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/6\/815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,30]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["pharmaceutics13060815"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13060815","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,30]]}}}